000640 — Dong-A Pharmaceutical Share Price
Last trade - 00:00- KR₩604bn
- KR₩1tn
- KR₩1tn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.48 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -0.48% | ||
| Dividend Yield (f) | 1.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.51 | ||
| Price to Tang. Book | 0.55 | ||
| Price to Free Cashflow | 3.27 | ||
| Price to Sales | 0.4 | ||
| EV to EBITDA | 5.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.21% | ||
| Return on Equity | 7.44% | ||
| Operating Margin | 7.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 881,944.08 | 1,014,860.9 | 1,132,002.86 | 1,333,229.64 | 1,429,766.81 | 1,561,249 | 1,689,218 | 12.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +68.4 | -65.69 | +274.52 | -20.48 | +94.46 | -18.02 | +4.41 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dong-A Pharmaceutical Co.,Ltd., formerly Dong-A Socio Holdings Co., Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company operates its business through six segments. The General Pharmaceutical and Quasi-Drug segment manufactures and sells products such as tonics, vitamins, cold remedies, and oral hygiene products. The Logistic segment is mainly engaged in freight, courier, car transportation, freight warehousing and leasing business. The Packaging Container and Bottled Water segment provides glass, glass products, bottled water and other beverages. The Biosimilar and Contract Manufacture segment is involved in the contract manufacture and development of biosimilar pharmaceuticals. The Holding Company segment is mainly engaged in holding company operations and management consulting services. The Other segment is involved in information technology solution and real estate development business.
Directors
- Sin Ho Kang CMG (86)
- Jong Hyeon Han PRE (54)
- Jae Hun Jung VPR (50)
- Min Yeong Kim MDR (49)
- Su Jeong Park MDR (54)
- Seong Geun Park OTH (53)
- Yi Hwan Kim OTH (45)
- Seung Hyeon Goh DRC (46)
- Sang Hwan Baek DRC (49)
- Bong Sun Cho NID (55)
- Gyeong Bae Gwon NID (51)
- Dong Cheol Kim NID (47)
- Chang Jin Moon NID (68)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- August 9th, 1949
- Public Since
- February 10th, 1970
- No. of Shareholders
- 10,223
- No. of Employees
- 273
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 6,729,857
- Address
- 64, Cheonho-daero, Dongdaemun-gu, SEOUL, 02587
- Web
- https://www.donga.co.kr
- Phone
- +82 29208114
- Auditors
- Samil Accounting Corp.
Latest News for 000640
Upcoming Events for 000640
Q3 2026 Dong-A Pharmaceutical Co.,Ltd. Earnings Call (Korean)
Q3 2026 Dong-A Socio Holdings Co Ltd Earnings Release
Q4 2026 Dong-A Socio Holdings Co Ltd Earnings Release
Dong-A Socio Holdings Co Ltd Annual Shareholders Meeting
Similar to 000640
Aprogen Biologics
Korea Exchange - KSE
Bionote
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
FAQ
As of Today at 02:19 UTC, shares in Dong-A Pharmaceutical are trading at KR₩89,800. This share price information is delayed by 15 minutes.
Shares in Dong-A Pharmaceutical last closed at KR₩89,800 and the price had moved by -15.53% over the past 365 days. In terms of relative price strength the Dong-A Pharmaceutical share price has underperformed the FTSE Developed Asia Pacific Index by -37.27% over the past year.
The overall consensus recommendation for Dong-A Pharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Dong-A Pharmaceutical dividend yield is 1.86% based on the trailing twelve month period.
Last year, Dong-A Pharmaceutical paid a total dividend of KR₩1,671, and it currently has a trailing dividend yield of 1.86%. We do not have any data on when Dong-A Pharmaceutical is to next pay dividends.
We do not have data on when Dong-A Pharmaceutical is to next pay dividends. The historic dividend yield on Dong-A Pharmaceutical shares is currently 1.86%.
To buy shares in Dong-A Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩89,800, shares in Dong-A Pharmaceutical had a market capitalisation of KR₩604bn.
Here are the trading details for Dong-A Pharmaceutical:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 000640
Based on an overall assessment of its quality, value and momentum Dong-A Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dong-A Pharmaceutical is KR₩147,816. That is 64.61% above the last closing price of KR₩89,800.
Analysts covering Dong-A Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of KR₩13,376 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dong-A Pharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -9.4%.
As of the last closing price of KR₩89,800, shares in Dong-A Pharmaceutical were trading -5.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dong-A Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 6.48. The shares last closed at KR₩89,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dong-A Pharmaceutical's management team is headed by:
- Sin Ho Kang - CMG
- Jong Hyeon Han - PRE
- Jae Hun Jung - VPR
- Min Yeong Kim - MDR
- Su Jeong Park - MDR
- Seong Geun Park - OTH
- Yi Hwan Kim - OTH
- Seung Hyeon Goh - DRC
- Sang Hwan Baek - DRC
- Bong Sun Cho - NID
- Gyeong Bae Gwon - NID
- Dong Cheol Kim - NID
- Chang Jin Moon - NID